Literature DB >> 8546202

Localization of type I procollagen gene expression in silica-induced granulomatous lung disease and implication of transforming growth factor-beta as a mediator of fibrosis.

T J Mariani1, J D Roby, R P Mecham, W C Parks, E Crouch, R A Pierce.   

Abstract

We have used the silica-induced model of pulmonary injury in the rat to study the pattern of collagen expression in granulomatous lung inflammation. A single intratracheal instillation of silica into adult rats resulted in granulomatous inflammation leading to fibrosis and alveolar proteinosis. The development of disease in these animals was characterized over a 27-day period after treatment by means of histological, biochemical, and molecular analyses. Biochemical analyses indicated that significant increases in the weights of silicotic lungs were due to elevated amounts of DNA and total protein. Analysis of hydroxyproline content showed a 15-fold increase in this amino acid in silicotic lungs, confirming the development of a fibrotic reaction. In situ hybridization for type I procollagen mRNA displayed increased gene expression in the parenchyma, conducting airways, and vasculature of silicotic rats. Within the parenchyma, type I procollagen was expressed uniquely within granulomatous lesions. Immunohistochemistry indicated type I procollagen was being expressed by an alpha-smooth muscle actin-negative population of cells. Immunolocalization of extra-cellular transforming growth factor-beta showed coincident temporal and spatial overlap with type I procollagen expression, implicating this cytokine as a mediator of collagen gene expression in this model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546202      PMCID: PMC1861615     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

Review 1.  Silicosis.

Authors:  W G Graham
Journal:  Clin Chest Med       Date:  1992-06       Impact factor: 2.878

2.  Collagen synthesis in granuloma annulare.

Authors:  M Kallioinen; M Sandberg; T Kinnunen; A Oikarinen
Journal:  J Invest Dermatol       Date:  1992-04       Impact factor: 8.551

3.  Role of extracellular matrices, matrix receptors, and cytokines in granulomatous lung inflammation.

Authors:  R L Perez; Y J Jeon; G W Staton; J Roman
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

4.  Characterization of excessive collagen production during development of pulmonary fibrosis induced by chronic silica inhalation in rats.

Authors:  E I Vuorio; J K Makela; T K Vuorio; A Poole; J C Wagner
Journal:  Br J Exp Pathol       Date:  1989-06

5.  In situ expression of transforming growth factor beta in streptococcal cell wall-induced granulomatous inflammation and hepatic fibrosis.

Authors:  C L Manthey; J B Allen; L R Ellingsworth; S M Wahl
Journal:  Growth Factors       Date:  1990       Impact factor: 2.511

6.  Temporal and spatial immunolocalization of cytokines in murine chronic granulomatous tissue. Implications for their role in tissue development and repair processes.

Authors:  I Appleton; A Tomlinson; P R Colville-Nash; D A Willoughby
Journal:  Lab Invest       Date:  1993-10       Impact factor: 5.662

7.  Surfactant protein D. Increased accumulation in silica-induced pulmonary lipoproteinosis.

Authors:  E Crouch; A Persson; D Chang; D Parghi
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

8.  Influences of endogenous and exogenous TGF-beta on elastin in rat lung fibroblasts and aortic smooth muscle cells.

Authors:  S E McGowan
Journal:  Am J Physiol       Date:  1992-08

9.  Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer.

Authors:  A O Williams; K C Flanders; U Saffiotti
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

10.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Authors:  T J Broekelmann; A H Limper; T V Colby; J A McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

View more
  7 in total

1.  Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia.

Authors:  Edwin Roger Parra; Walcy R Teodoro; Ana Paula Pereira Velosa; Cristiane Carla de Oliveira; Natalino Hajime Yoshinari; Vera Luiza Capelozzi
Journal:  J Histochem Cytochem       Date:  2006-08-21       Impact factor: 2.479

2.  Alteration of fibroblast phenotype by asbestos-induced autoantibodies.

Authors:  Jean C Pfau; Sheng'ai Li; Sara Holland; Jami J Sentissi
Journal:  J Immunotoxicol       Date:  2011-04-04       Impact factor: 3.000

3.  Annexin A1 mimetic peptide controls the inflammatory and fibrotic effects of silica particles in mice.

Authors:  P G Trentin; T P T Ferreira; A C S Arantes; B T Ciambarella; R S B Cordeiro; R J Flower; M Perretti; M A Martins; P M R Silva
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

4.  Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung injury.

Authors:  T J Mariani; S Sandefur; J D Roby; R A Pierce
Journal:  Mol Biol Cell       Date:  1998-06       Impact factor: 4.138

Review 5.  Interstitial fibrosis and growth factors.

Authors:  J A Lasky; A R Brody
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

6.  The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis.

Authors:  Virginie Barbarin; Aurélie Nihoul; Pierre Misson; Mohammed Arras; Monique Delos; Isabelle Leclercq; Dominique Lison; Francois Huaux
Journal:  Respir Res       Date:  2005-10-07

7.  Rapamycin inhibits transforming growth factor β1-induced fibrogenesis in primary human lung fibroblasts.

Authors:  Yu Gao; Xuefeng Xu; Ke Ding; Yan Liang; Dianhua Jiang; Huaping Dai
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.